UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), exercised 9,500 stock options at $135.42 and sold 9,500 common shares around $524–$533 on July 14, 2026 under a 10b5-1 plan.

On July 14, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 per share and received 9,500 shares of common stock, then sold 9,500 shares on the same day in a series of open-market transactions at prices ranging from approximately $524.15 to $532.60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The exercise added 9,500 shares to her directly held position at a low strike cost, while the subsequent sales monetized roughly the same number of shares at prevailing market prices, leaving her with 40,513 shares held directly and substantial additional indirect holdings through various family trusts and her spouse. The filing notes that the trading plan contemplates further exercises of options expiring March 15, 2027, through the earlier of the full exercise of 1,734,410 options or December 31, 2026.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000098

Alert Tier

6